I'll research FTV (Fortive) before writing the preview. Let me gather recent filings, transcripts, and news.Let me get recent stock price data and any recent news/analyst activity.# Fortive (FTV) — Q2 2026 Earnings Preview Report date: Wednesday, July 29, 2026 (2026Q2 Earnings Call) · Last close (7/28): $64.11
This is the fourth quarter of "New Fortive" reporting after the June 28, 2025 spin-off of the Precision Technologies segment (now Ralliant), which left Fortive as a ~$4.3B-revenue, two-segment company (Intelligent Operating Solutions and Advanced Healthcare Solutions) run by CEO Olumide Soroye and CFO Mark Okerstrom. The stock has been a strong performer — up roughly 26% from ~$51 immediately post-spin to a new high of $64.11 into the print, and up ~16% YTD from a $55 year-end 2025 base. Expectations are elevated, so the bar for a positive reaction is high. The central question tomorrow: does management convert its "trending toward the upper half" of the FY26 EPS range into an outright guidance raise?
On the Q1 call (4/30), management reaffirmed FY26 adjusted EPS of $2.90–$3.00 and said results were "trending toward the upper half of that range." They also said core growth of 2–3% is "trending towards the upper end." With the stock at highs, investors will likely need one of two things to stay constructive: - A formal raise/narrowing of the EPS range (e.g., to the upper half or above $3.00), and/or - Confirmation of core growth toward/above 3%.
A simple reaffirmation with the same "upper half" language may be treated as a disappointment given where the stock trades.
Management explicitly guided Q2 and Q3 adjusted EPS to be "broadly similar" to Q1's $0.70. This is unusual (Q2 normally steps up seasonally) and reflects two mechanical items: - Q1 got an ~150 bps tailwind from extra selling days that does not repeat in Q2. - Q2 has an easier comp and an ~150 bps combined FX + M&A tailwind to reported revenue. - Modeling notes: Q2 tax rate in the mid-teens, full-year net interest ~$135M.
So ~$0.70 in Q2 adjusted EPS is the anchor. The quality of the beat matters more than the headline — watch core (organic) growth ex-selling-days, which normalized to roughly mid-single-digit levels in Q1.
The most encouraging Q1 tell was that orders grew faster than the 5.3% core / 7.7% reported revenue, broad-based across Fluke, FAL, Industrial Scientific and ASP. Fluke book-to-bill was >1 with healthy backlog and normalizing channel inventory. Any deceleration in orders or book-to-bill would be a red flag; continued >1 book-to-bill supports the second-half growth narrative.
Intelligent Operating Solutions (~70% of revenue; Fluke is ~40% of the whole company): - Data center theme at Fluke — the CertiFiber Max launch is driving pull-through of power quality, battery, imaging and calibration tools. This is the key structural growth story; look for hard data points/spec-in progress with hyperscalers. - Facility & Asset Lifecycle (ServiceChannel, Gordian) — grew faster than the segment in Q1, led by ServiceChannel; AI features are being framed as a growth driver, not a threat. Watch ARR/GDR/NDR commentary. - Gordian's June quarter is seasonally important due to state/local government fiscal year-end. Management said nothing "extra normal" is baked into guidance, so this is a potential Q2 upside swing factor after a weak comp last year. - Gas detection (Industrial Scientific) — Hardware-as-a-Service share gains; Middle East rebuild demand is an emerging (small) tailwind.
Advanced Healthcare Solutions (~30%; ASP sterilization + Provation software): - Capital equipment recovery — low-temperature sterilization capital showed modest sequential improvement, but hospital capex remains cautious. Q2 is the key quarter because Fortive laps the weak Q2 2025 (reimbursement-policy-driven) comp — management flagged a favorable setup. - Consumables and software are the durable growth engines; software again grew faster than the company. Made-in-region (China/India) initiatives are an incremental tailwind.
Q1 adjusted EBITDA margin expanded ~140 bps to 29.3%, but adjusted gross margin fell ~100 bps on the net impact of tariffs. Management said the tariff drag persists into part of Q3 (when fully countermeasured), then dissipates in Q4. Also note the phasing warning: less margin expansion in 2H as comps toughen in Q3 and the Q4 selling-days headwind hits ($15–20M revenue drag). The medium-term framework calls for 50–100 bps of annual EBITDA margin expansion — watch that price/cost stays positive (was >1% in Q1).
Fortive has repurchased ~$1.8B (~35M shares, >10% of the float) since the spin, ~$500M/quarter, taking diluted shares to ~309M. This is a meaningful EPS tailwind. Watch for: - Continued buyback pace (leverage was 2.8x gross debt/EBITDA in Q1 — some room but rising via commercial paper). - M&A progress — new global corp-dev head Corbin Walburger joined; management is rebuilding a bolt-on pipeline. Any first sizable bolt-on would shift the capital-allocation narrative. - TTM free cash flow ~$954M with >100% conversion supports the program.
| Metric | Q1 2026 actual | Q2 bogey / context |
|---|---|---|
| Adjusted EPS | $0.70 (+25%) | ~$0.70 ("broadly similar to Q1") |
| Core revenue growth | +5.3% (incl. ~150 bps selling days) | Mid-single ex-days; FY 2–3% trending to top end |
| Reported revenue | $1.07B | FY ~$4.3B; Q2 ~150 bps FX+M&A tailwind |
| Adj. EBITDA margin | 29.3% (+140 bps) | Watch tariff drag on gross margin |
| FY26 adj EPS guide | $2.90–$3.00, "upper half" | Raise vs. reaffirm = key catalyst |
Fortive enters the print with genuine operating momentum — accelerating orders, a credible data-center/software growth story, aggressive buybacks, and easing AHS comps. But the stock is at an all-time high and already discounts a lot of that good news. The most likely path to a positive reaction is an explicit guidance raise (or a move above $3.00) plus confirmation that core growth is heading toward/above 3% and that orders/book-to-bill remain healthy. Watch the tariff-driven gross-margin cadence and the 2H margin phasing so a strong Q2 headline isn't undercut by cautious back-half framing. Gordian's June government spend and the pace of hospital capital recovery are the two swing factors most likely to determine whether the quarter beats or merely meets.
Note: I was unable to find fresh sell-side or news headlines in the days immediately before the print, so this preview is built primarily from Q1 2026 results/guidance, the June 2025 Investor Day framework, and the stock's price action.